


GOIDTS, VIOLAINE, DR. BIOL. HUM.

GENERAL INFORMATION

	<p>Junior Research Group Leader German Cancer Research Center Junior Research Group Brain Tumor Translational Targets Im Neuenheimer Feld 580, 69120 Heidelberg, Germany</p>	A06
---	---	-----

ACADEMIC EDUCATION & QUALIFICATION

Year(s)	Education
2010	Modul „Lehren und Lernen I + II“ des Baden-Württemberg Zertifikats Hochschullehre
2001-2003	Master degree in Molecular Biology University of Namur (BELGIUM) University of Uppsala (SWEDEN)
1999-2001	Candidate degree in Biological sciences University of Namur (BELGIUM)

SCIENTIFIC EDUCATION & QUALIFICATION

Year(s)	Education
2003-2006	Ph.D. Thesis Department of Human Genetics, University of Ulm (GERMANY). Under the supervision of Prof. Dr. H. Hameister. Grade: Summa Cum Laude (2006)
2002-2003	Diploma Thesis Department of Genetics, Dana Farber Cancer Institute, Harvard Medical School (USA) Under the supervision of Prof. Dr. M. Vidal (2003)

PROFESSIONAL EXPERIENCE

Year(s)	Experience
2015-to date	Junior Research Group Leader Head of the DKFZ Junior Research Group “Brain Tumor Translational Targets”
2010-2015	Group leader Division of Molecular Genetics (B060), DKFZ
2006-2010	Postdoc Division of Molecular Genetics (B060), DKFZ

OTHER QUALIFICATIONS/ROLES/RESPONSIBILITIES

Year(s)	
2010-present	Faculty member of the undergraduate program „Major Cancer Biology“ from the DKFZ
2010-present	Member of AcademiaNet, the Portal to Excellent Women Academics
2009-present	Mentee from the Helmholtz-Mentoring-Programm für weibliche Nachwuchskräfte “In Führung gehen”, Berlin, GERMANY
2007	Young Investigator Award Medical Faculty of the University of Heidelberg (3 years)
2007	Research fellowship DFG (Deutsche Forschungsgemeinschaft), declined
2006	Research fellowship Intramural funding program from the DKFZ (1 year)

SELECTED PUBLICATIONS

1. Campos B, Wan F, Farhadi M, Ernst A, Zeppernick F, Tagscherer KE, Ahmadi R, Lohr J, Dictus C, Gdynia G, Combs SE, [Goidts V](#), Helmke BM, Eckstein V, Roth W, Beckhove P, Lichter P, Unterberg A, Radlwimmer B, Herold-Mende C. Differentiation therapy exerts antitumor effects on stem-like glioma cells. **Clin Cancer Res** 2010;16, 2715-2728.
2. [Goidts V](#), Bageritz J, Puccio L, Nakata S, Zapatka M, Barbus S, Toedt G, Campos B, Momma S, Herold-Mende C, Lichter P, Radlwimmer B. RNAi screening in glioma stem-like cells identifies PFKFB4 as a key molecule important for cancer cell survival. **Oncogene** 2012;31, 3235-3243
3. Augustin I, [Goidts V](#), Bongers A, Kerr G, Vollert G, Radlwimmer B, Hartmann C, Herold-Mende C, Reifenberger G, von Deimling A, Boutros M. The Wnt secretion protein Evi/Gpr177 promotes glioma tumorigenesis. **EMBO Mol Med** 2012;4, 38-51.
4. Nakata S, Campos B, Bageritz J, Lorenzo Bermejo J, Becker N, Engel F, Acker T, Momma S, Herold-Mende C, Lichter P, Radlwimmer B, [Goidts V](#). LGR5 is a marker of poor prognosis in glioblastoma and is required for survival of brain cancer stem-like cells. **Brain Pathol** 2013;23(1), 60-72
5. Bageritz J, Puccio L, Piro RM, Hovestadt V, Phillips E, Pankert T, Lohr J, Herold-Mende C, Lichter P, [Goidts V](#). Stem cell characteristics in glioblastoma are maintained by the ecto-nucleotidase E-NPP1. **Cell Death Differ** 2014;21(6), 929-940
6. Nakata S, Phillips E, [Goidts V](#). Emerging role for leucine-rich repeat-containing G-protein-coupled receptors LGR5 and LGR4 in cancer stem cells. **Cancer Manag Res** 2014;6, 171-180. Review.
7. Cheng P, Phillips E, Kim S-H, Taylor D, Hielscher T, Puccio L, Hjelmeland A, Lichter P, Nakano I (*), [Goidts V](#). Kinome-wide shRNA Screen Identifies the Receptor Tyrosine Kinase AXL as a Key Regulator for Mesenchymal Glioblastoma Stem-Like Cells. **Stem Cell Rep** 2015; 4,899-913
8. Kim SH, Ezhilarasan R, Phillips E, Gallego-Perez D, Sparks A, Taylor D, Ladner K, Furuta K, Sabit H, Chhipa R, Cho JH, Beck S, Kurozumi K, Kuroiwa T, Iwata R, Asai A, Kim J, Sulman EP, Cheng S, Lee LJ, Nakada M, Guttridge D, DasGupta B, [Goidts V](#), Bhat KP, Nakano I. Serine/Threonine kinase MLK4 determines Mesenchymal Identity in Glioma Stem Cells in an NF- κ B-dependent manner. **Cancer Cell** 2016;29, 201-213
9. Phillips E, Lang V, Bohlen J, Bethke F, Puccio L, Tichy D, Herold-Mende C, Hielscher T, Lichter P, [Goidts V](#). Targeting atypical protein kinase C iota reduces viability in glioblastoma stem-like cells via a notch signaling mechanism. **Int J Cancer** 2016;139, 1776-1787
10. Wang J, Cheng P, Pavlyukov MS, Yu H, Zhang Z, Kim SH, Minata M, Mohyeldin A, Xie W, Chen D, [Goidts V](#), Frett B, Hu W, Li H, Shin YJ, Lee Y, Nam DH, Kornblum HI, Wang M, Nakano I. Targeting NEK2 attenuates glioblastoma growth and radioresistance by destabilizing histone methyltransferase EZH2. **J Clin Invest** 2017;127, 3075-3089

PATENTS

- Goidts, Bethke, Balss, Phillips: Development of a screening method to identify small-compound inhibitor to inhibit PFKFB4 function (WO2019/145496)